Clinical features of oral chemotherapy: Results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK

European Journal of Cancer Care

Volumn 19, Issue 4, 2010, Pages 425-433

  Brearley, S G ^a   Craven, O ^b   Saunders, M ^b   Swindell, R ^b   Molassiotis, A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Capecitabine; Colorectal cancer; Deferrals; Dose; Toxicity

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST TUMOR; COLORECTAL TUMOR; DOSE RESPONSE; FEMALE; HUMAN; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; SOCIOECONOMICS; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 77954764844     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2009.01114.x     Document Type: Article

References (20)

1. Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clinical Journal of Oncology Nursing 2003, 7(6):5-9. Suppl.
2. Bedell CH, Hartigan KJ, Wilkinson KL, Halpern IM. Oral chemotherapy: progress with challenges. Hematology Oncology News and Issues 2002, 1:28-32.
3. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendrick J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology 2002, 13:566-575.
4. Scientific discussion. 2005, http://www.emea.europa.eu/humandocs/PDFs/EPAR/Xeloda/282200en6.pdf, European Medicines Agency (EMEA), Available at: (accessed 13 June 2008
5. Annex 1: Summary of product characteristics. 2008, http://www.emea.europa.eu/humandocs/PDFs/EPAR/Xeloda/H-316-PI-en.pdf, European Medicines Agency (EMEA), Available at: (accessed 13 June 2008
6. Faithfull S, Deery P. Implementation of capecitabine (Xeloda®) into a cancer centre: UK experience. European Journal of Oncology Nursing 2004, 8(1):S54-S62. Suppl.
7. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Journal of Clinical Oncology 2001, 19:2282-2292.
8. Jones L, Westwood M, Wright K, Riemsma R, Hawkins N, Richardon G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer. 2002, http://www.nice.org.uk/nicemedia/pdf/assessmentreport_Capecetabine.pdf, Available at: (accessed 19 February 2008
9. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®). European Journal of Oncology Nursing 2004, 8(1):S31-40. Suppl.
10. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology 1997, 15:110-115.
11. MacLeod A, Branch A, Cassidy J, McDonald A, Mohammed N, MacDonald L. A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: Results of a prospective audit and retrospective survey of patient experiences. European Journal of Oncology Nursing 2007, 11:247-254.
12. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar-plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. American Journal of Clinical Dermatology 2000, 1:225-234.
13. Common Toxicity Criteria manual, common toxicity criteria v.2.0. 1999, http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf, National Cancer Institute (NCI), Available at: (accessed 7 August 2008
14. Common toxicity Criteria for Adverse Events (CTCAE) v.3.0. 2006, http://ctep.cancer.gov/forms/CTCAEv3.pdf, National Cancer Institute (NCI), Available at: (accessed 7 August 2008
15. Rapid response report: risks of incorrect dosing of oral anti-cancer medicines (support information). 2008, http://www.info.doh.gov.uk/SAR2/CMOPatie.nsf/vwDiscussionAll/977BEAA857F4F1DE802573D800517846?OpenDocument, National Patient Safety Agency (NPSA), NPSA/2008/RRR001, Available at: (accessed 4 June 2008
16. O'Shaughnessy J, Twelves C, Aapro M. Treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2002, 7(6):4-12. Suppl.
17. O'Shaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S. Randomized, open-label, phase II trial of oral capecitabine (Xeloda ®) vs.. a reference arm of intravenous CMF (cyclophosphomide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Annals of Oncology 2001, 12:1247-1254.
18. Scheithauer W, McKendrick J, Begbie S, Broner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, van Hazel G, Wong A, Zaluski J, Twelves C. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of Oncology 2003, 14:1735-1743.
19. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Journal of Clinical Oncology 2001, 19:4097-4106.
20. Webster-Gandy JD, Hoe C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. European Journal of Oncology Nursing 2007, 11:238-246.